<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193528</url>
  </required_header>
  <id_info>
    <org_study_id>Rosser-2015-7</org_study_id>
    <nct_id>NCT03193528</nct_id>
  </id_info>
  <brief_title>A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer</brief_title>
  <official_title>A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Rosser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA
      assay directed at a BCa-associated diagnostic signature in voided urine samples of patients
      with gross hematuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematuria is the most common presentation of BCa with 22% of patients with gross hematuria
      harboring BCa. VUC is the most widely used urine-based assay for detecting BCa; however, it
      fails to detect approximately 50% of low-grade or early stage BCa when it is most curable.

      Because of this severe limitation, patients with hematuria (microscopic or gross) will
      undergo an invasive examination of the urinary bladder, where a miniature camera is inserted
      into the bladder. We propose to improve upon the non-invasive detection of BCa by further
      validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in
      voided urine samples of patients with gross hematuria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the sensitivity and specificity of the multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples to reference standard of cystoscopy in a cohort of 450 participants presenting with gross hematuria.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the sensitivity and specificity of the multiplex ELISA assay to VUC and NMP22Â® BladderChek to reference standard of cystoscopy in this cohort.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To develop a BCa risk calculator from this cohort using cutting edge machine learning techniques (e.g., random forest) incorporating biomarker data and clinical data.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Bladder Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine collection (minimal 50 mL) and cystoscopy (+ biopsy w/in 4 weeks, if abnormal noted)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults, age 18 and older who have documented gross hematuria within the past 3 months who
        are referred for cystoscopy and are willing to participate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Have documented or reported gross hematuria within 3 month of study enrollment

          -  Willing and able to give written informed consent

        Exclusion Criteria (patients must not):

          -  Have history of BCa

          -  History of previous cancer (excluding basal and squamous cell skin cancer) within the
             past 3 years

          -  Have a known active urinary tract infection or urinary retention

          -  Have active stone disease (renal or bladder) or renal insufficiency (creatinine &gt;2.0
             mg/dL) Serum creatinine value can be up to 60 days before consent, otherwise repeat

          -  Have ureteral stents, nephrostomy tubes or bowel interposition

          -  Have recent genitourinary instrumentation (within 10 days prior to signing consent)

          -  Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and
             upper tract imaging)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Rosser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Rosser, MD</last_name>
    <phone>310-423-5609</phone>
    <email>charles.rosser@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Oppenheim</last_name>
      <phone>310-423-3713</phone>
      <email>Amy.Oppenheim@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yair Lotan</last_name>
      <phone>214-648-0389</phone>
      <email>yair.lotan@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Nara Medical University</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Anai</last_name>
      <phone>+81-744-22-3051</phone>
      <email>sanai@naramed-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 17, 2017</study_first_submitted>
  <study_first_submitted_qc>June 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Charles Rosser</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

